The European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) seeking the approval of obecabtagene autoleucel (obe-cel; formerly AUTO1) for use in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). Source: OncLive 2/4/2024